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Background: Chronic Allograft Nephropathy (CAN) is a clinical entity of progressive kidney transplant injury. The
defining histology is tubular atrophy with interstitial fibrosis (IFTA). Using a meta-analysis of microarrays from 84
kidney transplant biopsies, we revealed growth factor and integrin adhesion molecule pathways differentially
expressed and correlated with histological progression. A bioinformatics approach mining independent datasets
leverages new and existing data to identify correlative changes in integrin and growth factor signaling pathways.
Results: Analysis of CAN/IFTA Banff grades showed that hepatocyte growth factor (HGF), and epidermal growth
factor (EGF) pathways are significantly differentially expressed in all classes of CAN/IFTA. MAPK-dependent pathways
were also significant. However, the TGFβ pathways, albeit present, failed to differentiate CAN/IFTA progression.
The integrin subunits β8, αv, αμ and β5 are differentially expressed, but β1, β6 and α6 specifically correlate
with progression of chronic injury. Results were validated using our published proteomic profiling of CAN/
IFTA.
Conclusions: CAN/IFTA with chronic kidney injury is characterized by expression of distinct growth factors
and specific integrin adhesion molecules as well as their canonical signaling pathways. Drug target mapping
suggests several novel candidates for the next generation of therapeutics to prevent or treat progressive
transplant dysfunction with interstitial fibrosis.
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Chronic Allograft Nephropathy (CAN) is defined as a
clinical entity by chronic kidney injury leading to pro-
gressive loss of kidney transplant function in the absence
of another known cause. In histological terms, the find-
ings on a biopsy that match this clinical presentation are
interstitial fibrosis and tubular atrophy (IFTA) based on
the Banff ’05 classification [1]. We will refer to this en-
tity as CAN/IFTA to respect both the clinical and patho-
logical definitions. More recently, several groups have
observed that histological IFTA with interstitial inflam-
mation identifies the patients at highest risk for graft
loss [2-5]. It is suggested that this latter presentation,* Correspondence: smkurian@scripps.edu
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reproduction in any medium, provided the orIFTA/inflammation is a workable definition of chronic
rejection. It remains uncertain whether all CAN/IFTA
with progressive kidney dysfunction is a consequence of
immune-mediated chronic rejection or whether there
are yet additional mechanisms to discover.
Grading IFTA histology is a means of expressing the se-
verity of chronic kidney injury. Fibrosis represents the end
result of kidney tissue injury, which includes the donor or-
gan’s history, impact of ischemia/reperfusion, alloimmune-
activated T and B cell-mediated, antibody-mediated and
inflammation-mediated vascular injury [6-8]. Regardless
of the proximate causes, interactions between growth
factors and integrin adhesion molecules are important
mechanisms in the cycle of injury, repair and fibrosis
that are also widely accepted as downstream events in
CAN/IFTA [8-13].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and the mapping of functional pathways using gene ex-
pression array data generated in our own laboratory as
well as two independent, external datasets (total 84 kid-
ney transplant biopsies). The general aim of a meta-
analysis is to more powerfully estimate the true “effect
size” than possible with a single study. There have been
other studies that have looked at the gene expression in
CAN/IFTA using microarrays. In one study, two inde-
pendent CAN/IFTA data sets from the public domain
(22 and 14 biopsies, respectively) were used to identify
309 genes that were differentially expressed in CAN/
IFTA and were tested as predictors of CAN/IFTA on an
additional set of 6 biopsies [14]. By applying Fisher’s
exact test to identify enriched KEGG pathways, 6 differ-
ent KEGG pathways, all metabolism related, were over-
represented. A second study of 24 IF/TA biopsies showed
that differentially expressed genes were associated with
immune response, inflammation, and matrix deposition
[15]. Another study looked at gene expression in CAN/
IFTA biopsies describing “pathogenesis-based transcript
sets” for injured/diseased tissue [16]. Profiling of 150
kidney transplant biopsies to study the impact of inflam-
mation with fibrosis, showed that Toll-like receptor
signaling, antigen presentation/dendritic cell matur-
ation, IFN-gamma-inducible response and cytotoxic T
lymphocyte-associated changes were associated with in-
flammatory changes [4].
In the current study we focused on identifying the
differentially expressed growth factor and integrin sig-
naling pathways since there has not been any previous
meta-analysis that has focused on these mechanisms
despite literature implicating individual growth factors
and integrins with CAN/IFTA. Our study covered biop-
sies representative of the early development of CAN/
IFTA (Banff grade 1) and the subsequent progression to
moderate and severe forms (Banff grades 2 and 3). These
new results identify specific growth factor and integrin
pathways that allowed us to map a number of potentially
novel and drug-able targets.
Results and discussion
There have been meta-analyses in kidney transplantation,
which have been published with specific focuses. The
meta-analysis done by Park et al., [17] focused on global
profiling using GEO datasets on a broad term called “kid-
ney rejection” that included acute as well as chronic rejec-
tion. A similar study that analyzed acute kidney rejection,
also used a small number of CAN (n = 7) samples and
looked at a predefined subset of acute rejection transcripts
(ARTS) and pathogenesis based transcripts (PBTs) in
these rejection types [18]. Finally another study, again pri-
marily of acute renal allograft rejection, looked at the ex-
pression of metzincins (METS), and metzincins andrelated genes (MARGS) in renal allograft biopsies using
four independent microarray data sets [19]. Their data sets
also included a small group (n = 7) of IFTA samples.
In the current study we specifically wanted to test the
hypothesis that a meta-analysis of CAN/IFTA samples
from different sources would confirm the role of specific
growth factors and/or integrin pathways and potentially
reveal new pathways correlative with the progression of
CAN/IFTA, which individual studies failed to identify
due to the limitations with small sample sizes. We
mapped the differentially expressed genes in the varying
grades of CAN/IFTA to molecular pathways with a spe-
cial emphasis on established growth factor and integrin
signaling pathways.
Growth factor pathway signaling
In the first comparison of Banff 0 (n = 25) vs. All CAN/
IFTA (Banff 1, 2&3; n = 59), class comparisons yielded
4683 differentially expressed probesets. The differential
expression and directionality of fold changes is mentioned
for each class comparison in Additional file 1: Tables S1,
Additional file 2: Table S2, Additional file 3: Table S3 and
Additional file 4: Table S4 for all the results discussed
below. Specifically, IPA identified that these 4683 genes
fall into 123 significant pathways (SD1). When we applied
a Benjamini Hochberg correction for multiple testing to
the pathway analysis, there were 74 pathways that were
significant (p < 0.05). In this comparison HGF, VEGF, Epi-
dermal Growth Factor (EGF), Insulin-like Growth Factor
1 (IGF-1), TGF-beta and Platelet-derived Growth Factor
(PDGF) signaling pathways were all significantly differen-
tially expressed, even with multiple testing correction.
The second comparison was Banff 0 (n = 25) vs. Banff
1(n = 14) (mild CAN/IFTA), which yielded 1430 signifi-
cantly differentially expressed probesets and 84 signifi-
cant pathways (SD2). HGF, PDGF, VEGF and EGF
signaling pathways were differentially expressed as in the
comparison to All CAN/IFTA samples. However, Fibro-
blast Growth Factor (FGF) was also found but the TGFβ
pathway was not significantly expressed.
The third comparison, Banff 0 (n = 25) vs. Banff 2&3
(n = 29) (moderate/severe CAN/IFTA), yielded 1978 sig-
nificantly differentially expressed probesets and 58 sig-
nificant pathways (SD3). The EGF, FGF, HGF and IGF-1
pathways were all significant. Again, the TGFβ pathway
was not significantly differentially expressed in this ana-
lysis. Finally, we compared mild to moderate/severe
CAN/IFTA (Banff 1; n = 25 vs. Banff 2&3; n = 29) and
revealed 1362 significantly differentially expressed genes
and 44 significant pathways total (SD4). Of 44 pathways
identified, there was only one growth factor pathway,
IGF-1, with 7 DE genes (p = 0.05; 5/7 DE genes were
upregulated in moderate/severe CAN/IFTA). However, it
is important to note here that the FDR ranges for this
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less robust gene expression profile statistically than any
of the other comparisons performed. Given that every-
thing else was technically the same for all comparisons,
we believe these results reflect the biology and demon-
strate that the differences between early and more
advanced CAN/IFTA as judged by non-quantitative hist-
ology in these studies were significantly less. It is pos-
sible that as quantitative digital histology becomes more
widely available [20] that future comparisons of early to
more advanced CAN/IFTA will be more robust.
In sum, the HGF and FGF signaling pathways were
significantly upregulated in early CAN/IFTA (Banff 0 vs.
1) and continued to be upregulated in moderate/severe
CAN/IFTA (Banff 0 vs. Banff 2&3). In contrast, it was
observed that the VEGF and PDGF signaling pathways
were only significantly upregulated in early CAN/IFTA
compared to Banff 0 biopsies and IGF1 was the only sig-
nificant growth factor pathway upregulated in moderate/
severe CAN/IFTA. Table 1 summarizes all the pathways
in these four different comparisons.
MAPK dependent growth factor signaling
Many growth factor pathways are dependent on mitogen-
activated protein kinase signaling (MAPK or extracellular-
signal-regulated kinase; ERK). We found that LPS-stimulatedTable 1 Growth factor signaling pathways significantly
differentially expressed between the Banff grades of
CAN/IFTA


















CAN Banff 1 vs. Banff 2&3 p-value
IGF-1 Signaling* 0.0447
*Significant in two comparisons.
$Significant in three or more comparisons.MAPK, ERK/MAPK and p38 signaling were only signifi-
cantly differentially expressed in the analysis of Banff 0 vs.
Banff 1, 2&3 CAN/IFTA. It is worth noting that MAPK
regulates signaling by TGFβ [21-23], VEGF [24-26], IGF-1
[27], and HGF [28-30]. These results further support the
analysis of the growth factor pathways above suggesting
the same pathways are engaged regardless of the histo-
logical severity of CAN/IFTA. The expression of the genes
in the TGF, IGF-1 and HGF pathways increased in expres-
sion from mild to more severe CAN/IFTA, but the oppos-
ite trend was seen with VEGF.
Integrin pathway and expression
Class comparisons of subjects with and without CAN/
IFTA (Banff 0 vs. Banff 1, 2&3) showed that six β-
integrin (1, 2, 3, 5, 6, 8) and six α-integrin subunits (v, μ,
1, 2, 6, 9) were upregulated. The canonical integrin sig-
naling pathway was also highly differentially expressed
in this comparison (p = 4.1 × 10-7). Comparisons of spe-
cific integrins significantly upregulated in early CAN/
IFTA (Banff 0 vs. Banff 1) revealed differential expres-
sion of β subunits 1, 5, 6 and 8, and α subunits v, 1, 6
and μ. With progression from mild to moderate/severe
CAN/IFTA (Banff 1 vs. Banff 2&3), the α2, α9, β1, and
β6 subunits were upregulated above the levels already
present early in CAN/IFTA. The only exception to the up-
regulation of integrin expression correlating with CAN/
IFTA progression was that integrin α6 was downregulated.
All results are summarized in Table 2.
Transcripts for the canonical integrin signaling path-
way were also significantly expressed in these latter two
comparisons. There are 187 genes in the canonical
integrin pathway. Interestingly, only 2 genes, PTEN and
PTENP1, were significantly correlated in all three com-
parisons of CAN/IFTA stages suggesting a potential
common signaling mechanism. Thirty-four integrin path-
way genes were significantly associated with both Banff 1
and Banff 2&3 CAN/IFTA and 20 genes were only associ-
ated with Banff 2&3 (Figure 1). In conclusion, many integ-
rin pathway molecules are highly expressed at an early
stage of CAN/IFTA and continue to be expressed during
the progression to more severe disease, while another set
are linked to only more advanced CAN/IFTA (Table 3).
To give some context with regards to the most signifi-
cant pathways associated with CAN/IFTA progression
from the current study we looked at the integrin, IGF
and EGF signaling pathways and their regulation with
respect to the progression of CAN/IFTA. For the integ-
rin pathway, we observed that in the Banff 0 vs. 1 com-
parison all differentially expressed genes in the pathway
were upregulated in the Banff 1 patients. When we com-
pared this to the expression of the same genes in the
Banff 1 vs. Banff 2,3 patients some of the genes like
TLN, JNK and CPN were downregulated in the Banff
Table 2 Integrin subunits differentially expressed
between the Banff grades of CAN/IFTA
B0 vs. 1 + 2 + 3 B0 vs. 1 B0 vs. 2 + 3 B1 vs. 2 + 3












All p-values are <0.005.
The direction of change is indicated by the arrow and the numbers in brackets
represent the magnitude of change for each integrin subunit. All results
shown were statistically significant with p values ranging from <1 × 10-3
to 10-7.
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and the IGF-1 pathways with PKC and JNK (HGF
pathway) being downregulated in the Banff 2,3 when
compared to Banff 1, and JNK (EGF pathway) was
downregulated in Banff 2,3 when compared to Banff 1,
respectively. These changes suggest that some of theseFigure 1 Integrin pathway molecules identified by the analysis of sta
those with CAN/IFTA. Genes in grey are differentially expressed whereas g
that most genes of the integrin pathway are differentially expressed in CAN
expressed both at the mRNA level as well as at the protein level by tandem
study by using the accumulation of spectral counts for each detected protgenes need not be overexpressed and that their down-
regulation in the Banff 2,3 group when compared to
Banff 1 could possibly be a mechanism that promotes
CAN/IFTA progression.Proteogenomic analysis of tissue biopsies
In order to validate the results of this gene transcription
profiling and functional pathway mapping at the protein
level, we turned to our previously published analysis of
CAN/IFTA biopsies using shotgun tandem mass spec-
trometry proteomics [31]. Of the 187 integrin pathway
molecules, 25 (14%) of them were identified as signifi-
cantly differentially expressed by proteomics (SD5)
(Additional file 5). In this context it is important to note
that we had already identified the whole integrin pathway
and specifically integrin β1 protein as a key player in CAN/
IFTA progression. In addition, proteins of the IGF-1
pathway were also significant in the progression from mild
to moderate/severe CAN/IFTA (Banff 1 vs. Banff 2,3;
p = 0.02) and with advanced CAN/IFTA (Banff 0 vs. Banff
2,3; p = 0.004) at the transcript level, which was similar to
what we found at the protein level with the IGF-1 pathway
being upregulated in the Banff 2,3 subjects, with tandem
mass spectrometry proteomics. Finally, in the development
of mild CAN/IFTA (Banff 0 vs. Banff 1), the VEGF and
EGF pathways were significant (p = 0.02 and 0.05, respect-
ively) by both transcript and protein.tistically significant genes between subjects without CAN/IFTA vs.
enes in white are not significantly differentially expressed. It is evident
/IFTA. The genes that are marked with thick arrows were differentially
mass spectroscopy proteomics. Protein levels were estimated in this
ein as we have previously published [31].
Table 3 An ANOVA analysis of integrin pathway genes significantly differentially expressed between CAN/IFTA Banff 0
(no CAN/IFTA), Banff 1 (mild CAN/IFTA) and Banff 2,3 (moderate severe CAN/IFTA)
Gene symbol Description Pairwise significance
Integrin subunits
ITGA1 integrin, alpha 1 (1, 2), (1, 3)
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) (1, 3)
ITGA6 integrin, alpha 6 (1, 2), (1, 3), (2, 3)
ITGA9 integrin, alpha 9 (1, 2), (1, 3)
ITGAD integrin, alpha D (2, 1), (3, 1)
ITGAM integrin, alpha M (complement component 3 receptor 3 subunit) (1, 2), (1, 3)
ITGAV integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) (1, 2), (1, 3)
ITGB1 integrin, beta 1 (fibronectin receptor, beta polypeptide, ) (1, 2), (1, 3), (2, 3)
ITGB2 integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) (1, 3)
ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) (1, 3)
ITGB5 integrin, beta 5 (1, 2), (1, 3)
ITGB6 integrin, beta 6 (1, 2), (1, 3), (2, 3)
ITGB8 integrin, beta 8 (1, 2), (1, 3)
Integrin signaling pathway molecules associated with all grades of CAN
PTEN phosphatase and tensin homolog (1, 2), (1, 3), (2, 3)
PTENP1 phosphatase and tensin homolog (mutated in multiple advanced cancers 1), pseudogene 1 (1, 2), (1, 3), (2, 3)
Integrin signaling pathway molecules associated with mild and moderate CAN but cannot distinguish mild from moderate CAN
ACTB actin, beta (1, 2), (1, 3)
ACTR2 ARP2 actin-related protein 2 homolog (yeast) (1, 2), (1, 3)
ACTR3 ARP3 actin-related protein 3 homolog (yeast) (1, 2), (1, 3)
ACTR3B ARP3 actin-related protein 3 homolog B (yeast) (1, 2), (1, 3)
ARF4 ADP-ribosylation factor 4 (1, 2), (1, 3)
ARF6 ADP-ribosylation factor 6 (1, 2), (1, 3)
ARPC1A actin related protein 2/3 complex, subunit 1A, 41 kDa (1, 2), (1, 3)
ARPC2 actin related protein 2/3 complex, subunit 2, 34 kDa (1, 2), (1, 3)
ARPC4 actin related protein 2/3 complex, subunit 4, 20 kDa (2, 1), (3, 1)
ARPC5 actin related protein 2/3 complex, subunit 5, 16 kDa (1, 2), (1, 3)
CAPN10 calpain 10 (2, 1), (3, 1)
CAPN6 calpain 6 (2, 1), (3, 1)
CRKL v-crk sarcoma virus CT10 oncogene homolog (avian)-like (1, 2), (1, 3)
GRB2 growth factor receptor-bound protein 2 (1, 2), (1, 3)
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (1, 2), (1, 3)
MYLK myosin, light chain kinase (1, 2), (1, 3)
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog (1, 2), (1, 3)
PAK2 p21 (CDKN1A)-activated kinase 2 (1, 2), (1, 3)
PAK7 p21(CDKN1A)-activated kinase 7 (2, 1), (3, 1)
PIK3C2A phosphoinositide-3-kinase, class 2, alpha polypeptide (1, 2), (1, 3)
PIK3C3 phosphoinositide-3-kinase, class 3 (1, 2), (1, 3)
PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide (1, 2), (1, 3)
PIK3CB phosphoinositide-3-kinase, catalytic, beta polypeptide (1, 2), (1, 3)
PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma) (1, 2), (1, 3)
PPP1CB protein phosphatase 1, catalytic subunit, beta isoform (1, 2), (1, 3)
PPP1CC protein phosphatase 1, catalytic subunit, gamma isoform (1, 2), (1, 3)
PPP1R12A protein phosphatase 1, regulatory (inhibitor) subunit 12A (1, 2), (1, 3)
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 (1, 2), (1, 3)
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Table 3 An ANOVA analysis of integrin pathway genes significantly differentially expressed between CAN/IFTA Banff 0
(no CAN/IFTA), Banff 1 (mild CAN/IFTA) and Banff 2,3 (moderate severe CAN/IFTA) (Continued)
RRAS2 related RAS viral (r-ras) oncogene homolog 2 (1, 2), (1, 3)
SOS2 son of sevenless homolog 2 (Drosophila) (2, 1), (3, 1)
TLN1 talin 1 (2, 1), (3, 1)
TSPAN3 tetraspanin 3 (2, 1), (3, 1)
TTN titin (2, 1), (3, 1)
WIPF1 WAS/WASL interacting protein family, member 1 (1, 2), (1, 3)
Integrin signaling pathway molecules specifically associated with moderate CAN
ARF1 ADP-ribosylation factor 1 (1, 3)
ARPC1B actin related protein 2/3 complex, subunit 1B, 41 kDa (1, 3)
ARPC5L actin related protein 2/3 complex, subunit 5-like (1, 3)
CAPN7 calpain 7 (1, 3)
GIT1 G protein-coupled receptor kinase interactor 1 (3, 1)
ILK integrin-linked kinase (3, 1)
ITGB3BP integrin beta 3 binding protein (beta3-endonexin) (1, 3)
MLCK MLCK protein (3, 1)
NCK2 NCK adaptor protein 2 (1, 3)
PAK3 p21 (CDKN1A)-activated kinase 3 (1, 3)
PIK3C2B phosphoinositide-3-kinase, class 2, beta polypeptide (1, 3)
PIK3CD phosphoinositide-3-kinase, catalytic, delta polypeptide (1, 3)
PIK3CG phosphoinositide-3-kinase, catalytic, gamma polypeptide (3, 1)
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) (1, 3)
PPP1CA protein phosphatase 1, catalytic subunit, alpha isoform (1, 3)
PPP1R12B protein phosphatase 1, regulatory (inhibitor) subunit 12B (3, 1)
SOS1 son of sevenless homolog 1 (Drosophila) (3, 1)
TSPAN4 tetraspanin 4 (1, 3)
TSPAN5 tetraspanin 5 (1, 3)
WASL Wiskott-Aldrich syndrome-like (3, 1)
Numbers in brackets represent the pair-wise comparison significance (p < 0.005) where 1 = Banff 0, 2 = Banff 1 and 3 = Banff 2,3.
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We used a new module in IPA based on literature and
public drug target databases to determine how many of
the molecules we identified by gene expression profiling
in CAN/IFTA are targeted by known drugs (SD6)
(Additional file 6). Of the 4109 differentially expressed
genes between Banff 0 vs. All CAN/IFTA, 129 genes are
targets of known drugs. In the differentially expressed
growth factor pathways (HGF, VEGF, EGF, IGF-1, TGF-β
and PDGF), 10 of the 78 molecules we identified are tar-
gets of known drugs. In the integrin pathway, there are
only 2 genes known to be targets of drugs (ITGB5 and
ITGAV) and both are differentially expressed in our data.
We also used Ingenuity to identify genes that are known
or potential biomarkers defined in the literature (SD7)
Additional file (7). For example, of the 78 molecules asso-
ciated with growth factor signaling, 34 (44%) of the genes
are biomarker candidates and 368 of the total 4109 differ-
entially expressed genes have been described as potential
biomarkers in the literature in various models of disease.The advantages of combining information from multiple
existing microarray studies in a meta-analysis are a larger
sample size, minimization of center-specific effects, and
the application of a single data analysis pipeline. Meta-
analyses also represent savings in time and costs by making
comprehensive use of already available data. The present
study represents a mechanism-focused, bioinformatics-
driven meta-analysis of gene expression in kidney trans-
plant biopsies with CAN/IFTA. We demonstrate that the
differential activation and expression of specific growth fac-
tors, integrins and signaling pathways distinguishes the dif-
ferent stages of CAN/IFTA and correlate with progression
of disease.
In our data, VEGF and PDGF signaling pathways were
significantly upregulated in early CAN/IFTA but were
not upregulated in biopsies with moderate/severe CAN/
IFTA. This is consistent with an increased expression of
VEGF in interstitial cells and arteries developing intimal
and adventitial fibrosis in kidneys undergoing vascular
rejection [32]. In contrast, only differential expression of
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(Banff 1) to moderate/severe CAN/IFTA (Banff 2&3). Per-
haps purposeful inhibition of IGF-1 signaling might be a
candidate for therapy once CAN/IFTA is already present.
However, these results also suggest that most of the
growth factor pathways driving CAN/IFTA are present
early in the course and not changing significantly as it
progresses. It is worth commenting that these results also
suggest caution that once patients present with early
CAN/IFTA (e.g. protocol biopsy), there is a high likeli-
hood that it will eventually progress.
Interestingly, TGFβ was only differentially expressed
when comparing healthy transplants (Banff 0) to those
with any grade of CAN/IFTA. However, TGFβ expression
does not distinguish between mild and moderate/severe
disease. Evidence for the early activation of TGFβ has
been shown in a number of studies as early as 2–6 months
and is often reviewed as a critical growth factor for inter-
stitial fibrosis [33,34]. A pediatric study showed that
relatively early TGFβ expression in grafts 100 days after
transplantation correlates with decreased long-term graft
function and increased graft fibrosis at 3 years [35].
siRNAs directed against the TGFβ receptor improved
renal fibrosis in a mouse model of interstitial nephritis
[36]. Our analysis is consistent with these studies in iden-
tifying differential TGFβ pathway expression in biopsies
with CAN/IFTA compared to healthy transplant biopsies.
However, the fact that there is no further increase in
TGFβ gene expression despite increasing severity of dis-
ease suggests that other pathways mediate progressive fi-
brosis and tubular atrophy.
The HGF and FGF signaling pathways were signifi-
cantly upregulated in early CAN/IFTA, but unlike TGFβ
were further upregulated in biopsies of moderate/severe
CAN/IFTA. HGF, a member of the FGF family, is known
to mediate the repair and maintenance of the kidney epi-
thelium. HGF is nephron-protective [37] and suppresses
interstitial fibrosis in a rat model of obstructive nephrop-
athy [38]. Exogenous administration of HGF has been
shown in a rat model of CAN to prevent the progression
of IFTA [39]. Thus, one possibility for our results in
these human patients is that up-regulation of the intrin-
sic HGF pathway acts as a compensatory mechanism
protecting the progression of chronic injury and fibrosis.
It adds caution to the tendency of advocating blockade
of any pathway found in any pathological condition.
FGF is known to stimulate endothelial cell prolifera-
tion, degrade ECM and interact with VEGF [40]. In situ
hybridization and immunohistochemical analysis showed
that mRNA for FGF-1 and its high-affinity receptors
were increased in the tubular epithelium, inflammatory
cell infiltrates, and neovascular structures of kidney
transplant patients who underwent nephrectomy after
graft loss for what the authors called chronic rejection[41]. Our results are consistent with this role for FGF-1
in biopsy-proven CAN/IFTA.
As already noted, VEGF and PDGF signaling pathways
were significantly upregulated with mild CAN/IFTA, but
not further upregulated with moderate/severe CAN/
IFTA. In a different set of transplant biopsies done sev-
eral years ago, we also demonstrated the up-regulation
of PDGF with CAN/IFTA [42]. Thus, it may be that
VEGF and PDGF signaling is important early in the es-
tablishment of chronic allograft injury, perhaps by amp-
lifying the injury driven by FGF-1.
The MAPK-dependent growth factor signaling pathways,
ERK and p38, were significantly differentially expressed in
our study between well functioning transplants vs. any
grade of CAN/IFTA. In rat models, the inhibition of p38
MAPK by treatment with a specific p38 MAPK inhibitor
resulted in reduced CAN/IFTA with preserved renal func-
tion and survival [43,44].
We also show that specific integrins are upregulated in
the progression of CAN/IFTA (Table 2) and these results
correlate with the parallel up-regulation of the canonical
integrin signaling pathway (Figure 1). The integrin sub-
units β1, β6 and α6 were consistently and significantly
differentially expressed in all comparisons. An earlier
study in rats demonstrated that blockade of interactions
between α4β1integrin and fibronectin prevents the de-
velopment of chronic rejection in cardiac allografts [45].
However, we note that our kidney results do not demon-
strate differential expression of the α4 chain. One ex-
planation is that the β1 subunit regulates the assembly
of the α4β1integrin in kidneys. A study of integrin expres-
sion in allograft rejection showed that αvβ6 was involved
in the re-epithelialization of healing isografts in an animal
model of chronic progressive lung allograft rejection [46].
In two other studies, mice with bleomycin-induced pul-
monary fibrosis were treated with an anti-αvβ6 monoclo-
nal antibody [47,48]. Treated animals showed reduced
fibrosis and these results were confirmed using transgenic
and knock-out animals. In a published meta-analysis of
human kidney transplant biopsies, 309 genes were identi-
fied as associated with CAN/IFTA [14]. We identified 47
genes from this set in the present analysis including
the α6 chain. Thus, these many lines of evidence con-
verge to identify roles for several specific growth factors
and integrin adhesion pathways in chronic kidney trans-
plant injury.
Our analysis of the correlation of the genomic findings
with our previously published proteomic work clearly
identified the integrin pathway (Figure 1) and the IGF-1
pathway as being differentially regulated and as pathways
that specifically affect CAN/IFTA progression. This is
very relevant because both these pathways are validated
both at the mRNA as well as the protein level and could
potentially be the highest priority pathways to address
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CAN/IFTA.
Finally, we used a new module in Ingenuity Pathway
Analysis to search for drug targets in our differentially
expressed genes and pathways (SD6). For example, in
the context of the integrins, there are three drugs that
target the integrin αv subunit, two antibodies and one
cyclic RGD pentapeptide and the pentapeptide also tar-
gets another differentially expressed integrin subunit, β5
[49]. Ten of 78 molecules involved in known growth fac-
tor signaling pathways (HGF, VEGF, EGF, IGF-1, TGF-β,
PDGF) were targets of over 30 different drugs. Many of
these drugs are already FDA-approved while others are
in various phases of clinical trials for cancer, hyperten-
sion and diabetes, including specific kinase inhibitors,
receptor signaling blockers and monoclonal antibodies.
The potential of using bioinformatic tools to integrate
public data with clinical gene profiling results and iden-
tify drug targets or candidate biomarkers is still largely
untested. However, two recent studies from Stanford
used a similar approach to identify drug targets for can-
cer, one of which they validated, or search for transplant
biomarkers [50,51].
We would also like to draw the attention of the
readers to some of the limitations of our study. First,
even though we used 84 samples to perform a meta-
analysis and despite the fact that we were adequately
powered to detect gene expression changes greater thanTable 4 Clinical characteristics for the 33 samples that were a
Banff0
Subject Numbers 9
Recipient Age ± SD‡ 49.7 ± 12.9
% Female Recipients 66.7
% Recipient African American 0
% Pre-tx Type II Diabetes 25
% PRA > 20 0
HLA Mismatch ± SD 2.3 ± 1.3
% Deceased Donor 66.7
Donor Age ± SD 31.4 ± 13.6
% Female Donors 33.3
% Donor African American 0
% Induction 66.7
Serum Creatinine ± SD 3.07 ± 1.2
Time to Biopsy (Days) ± SD 691 ± 550
% Calcineurin Inhibitors 87.5
% Mycophenolic Acid Derivatives 55.6
% Oral Steroids 44.5
C4d Positive Staining (%) 0
* Significance for all comparisons were determined with paired Students t-test for p
data comparisons by Chi-Square.
‡ SD = standard deviation from the mean.
^ NS = not significant (p ≥ 0.05).two-fold, the findings of the current study need to be
validated in a larger cohort of samples, especially of the
different subtypes of CAN before it can be generalized.
Similarly, we cannot discount the effect of different im-
munosuppressive drug regimens and levels on the gene
expression, though all the studied patients were on a
primary calcineurin inhibitor protocol. The correlations
between transcript levels and protein levels have been
shown to be relatively poor in earlier studies[52,53]; how-
ever several recent studies have shown that these correla-
tions are a lot better than previously shown due to the
technical advancements in protein detection by the latest
mass spectrometry technologies[54,55]. Our current study
used tandem mass spectrometry proteomics data from an
earlier study of ours using liquid chromatography coupled
with an ion trap instrument (MudPIT protocol for LC/
MS/MS) [31]. Newer technologies have significantly en-
hanced mass detection accuracies and targeted proteomics
using alternative mass spectrometry technologies such as
multiple single reaction monitoring (MSRM) and triple
quadropole TOF instruments will now allow investigators
to more accurately identify and even quantify protein
level changes for better correlations with gene expres-
sion levels profiled in the same samples. The import-
ance of the present work is to establish a clear set of
candidate genes and functional pathways that would
merit the next stage of experimental efforts to validate
these with proteomics.nalyzed with microarrays in our laboratory
CAN Significance*
24





2.6 ± 3.2 NS
69.6 NS




1.78 ± 1.1 0.01





air-wise comparisons of data with Standard Deviations and for dichotomous
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Putting the clinical potential of these drug candidate and
biomarker correlations into perspective, there are mul-
tiple lines of published scientific data that the growth
factor signaling pathways we describe here are highly
likely to be linked mechanistically to the development
and/or progression of CAN/IFTA. Clearly, we cannot
determine a root cause of CAN/IFTA simply by gene
profiling of biopsies. However, we are describing evi-
dence for multiple and powerful tissue injury and re-
modeling pathways linked to growth factors and integrin
adhesion molecules. The initiation and progression of
chronic allograft injury could be driven by immune-
mediated rejection through multiple mechanisms and
impacted upon by drug toxicities and concomitant med-
ical problems. Regardless, the possibility raised here is
that the integrins and growth factors identified in this
study are attractive candidates for developing animal
models to study the effects of their inhibition/activation.
Such work could be the starting point for translational
studies into how these molecules modulate signaling in
patients with early CAN/IFTA could be a successful way
of mitigating the damage caused by whatever the under-
lying primary mechanism may be and the large number
of known drug candidates available is encouraging.
Methods
Microarray analysis of tissue biopsies
DNA Microarray CEL files from 84 kidney transplant bi-
opsy samples were studied. We processed 33 samples
(24 CAN and 9 Banff0), and the others were from two
independent studies (GSE7392 (16 CAN and 14 Banff0)
[17] and GSE9493 (16 CAN) [18,19]) from the NIH
NCBI GEO repository. The clinical characteristics of the
33 samples processed by us are given in Table 4. All
samples were obtained as part of the Transplant Genom-
ics Collaborative Group (TGCG) and approved by the
review boards of the participating transplant centers
(Scripps Green Hospital, Cleveland Clinic Foundation,
Mendez National Institute for Transplantation, Mayo
Clinic Arizona and U Colorado Health Sciences). All sam-
ples were hybridized on Affymetrix HG-U133 Plus 2.0
Arrays to avoid cross-platform comparisons. We used
ComBat, a software that uses Bayes frameworks for
adjusting data for batch effects that is robust to outliers in
small sample sizes and performs comparable to existing
methods for large samples [56]. BRB Array Tools (version
3.8.1) was used to perform class comparisons between
classes (p value <0.005 defined as significant after multiple
testing adjustments. The resulting FDR ranges reported
for all but one comparison were from 1×10-7 to 6%. The
only exception to this FDR range was the comparison
done between early CAN (Banff1) vs. moderate to severe
CAN (Banff2,3) where the FDRs ranged from 14 to 19%,consistent with the conclusion that the identified gene
changes were much less robust for this comparison. De-
tails on the microarray data processing have been previ-
ously described [57]. Pathway, network and drug target
analysis was performed using Ingenuity Pathway Analysis
(IPA). Pathway significance was determined using a right-
tailed Fisher’s Exact Test, where only over-represented
functions or pathways are considered significant at a p
value ≤0.05.
Proteogenomic analysis of tissue biopsies
All proteomic data comparisons were made using our
previously published study that revealed about 1400 pro-
teins with unique expression profiles tracing the pro-
gression from normal transplant biopsies to increasingly
severe grades of CAN/IFTA [31].
Consent
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